Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S2352-3026(23)00056-X | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study.
Eur J Haematol
March 2024
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Melphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone demonstrated superior progression-free survival (PFS), but not overall survival (OS), versus pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma in the OCEAN study. Time to progression (TTP) <36 months after a prior autologous stem cell transplantation (ASCT) was a negative prognostic factor for OS with melflufen. This post hoc exploratory analysis evaluated patients refractory to prior alkylators (e.
View Article and Find Full Text PDFMelflufen: post-hoc subgroup analyses and the US FDA Oncologic Drugs Advisory Committee.
Lancet Haematol
May 2023
Program On Regulation, Therapeutics And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02120, USA; Harvard Medical School, Harvard University, Boston, MA, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!